Streetbeat News

Stock Prices

ABT

Abbott Laboratories reported Q2 2024 adjusted EPS of $1.14, beating the estimate of $1.10. Sales were $10.377 billion, also surpassing the estimate of $10.371 billion.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:32 am

OFG

OFG Bancorp reported Q2 2024 GAAP EPS of $1.08, beating the analyst consensus estimate of $0.96 by 12.5%. This represents a 16.13% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:31 am

SAI

SAI.TECH Global shares are trading higher following the company's Board authorization of a buyback of up to $1 million and up to 1 million shares.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:26 am

SPY

USO

VGK

Reuters reported that OPEC+ is unlikely to change its oil output policy at the August 1 JMMC meeting, according to sources.

Portfolio Pulse from charles@benzinga.com

July 18, 2024 | 11:24 am

LUXH

LuxUrban Hotels announced that the underwriter of its underwritten public offering has exercised its over-allotment option in full to purchase an additional 4.5 million shares at the public offering price of $0.17 per share.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:21 am

FTNT

Fortinet shares are trading higher after TD Cowen upgraded the stock from Hold to Buy.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:13 am

HXL

Hexcel Corporation has revised its FY24 outlook, lowering its adjusted EPS to $2.02-$2.18 from $2.10-$2.30 and its revenue forecast to $1.90B-$1.98B from $1.925B-$2.025B. Both revised figures are below analyst estimates.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:09 am

VIRT

Virtu Financial has declared a quarterly cash dividend of $0.24 per share, payable on September 15, 2024.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:07 am

AGEN

Agenus announced the outcomes of its End-of-Phase-2 meeting and topline interim Phase 2 data for its BOT/BAL combination. The company has reached an agreement with the FDA on the Phase 3 dose for this combination.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:07 am

IONS

Ionis Pharmaceuticals has completed enrollment in the pivotal trial of Zilganersen (ION373) for treating Alexander Disease, a rare neurological disorder. Topline data are expected in the second half of 2025.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:06 am